Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ipsen
Biotech
Ipsen fails to land pivotal rare disease trial
Ipsen’s miss follows Regeneron's phase 3 win in the same ultrarare indication. Regeneron said it planned for a FDA submission by the end of 2025.
Gabrielle Masson
Dec 19, 2025 3:37pm
Ipsen inks €1B buyout of French biotech ImCheck
Oct 22, 2025 10:33am
Ipsen taps Biomunex's MAITs to treat solid tumors in $610M bet
Dec 3, 2024 6:00am
Ipsen scores 2nd ADC via $1B biobucks pact with Foreseen
Jul 11, 2024 8:14am
Ipsen, Marengo ink $1.2B biobuck deal to treat cold tumors
Jun 7, 2024 9:15am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
